The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA. email@example.com
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(11):1902-6.
INTRODUCTION: Eicosanoids, including PGE-2 and 5-HETE, can increase levels of plasma vascular endothelial growth factor (VEGF). Overexpression of COX-2 or 5-LOX increases levels of PGE-2 and 5-HETE, respectively. Elevated levels of VEGF are common in patients with non-small cell lung cancer (NSCLC). We prospectively measured VEGF in serum collected from patients enrolled in Cancer and Leukemia Group B 30203, a randomized phase II study of eicosanoid modulation in addition to chemotherapy in patients with advanced NSCLC, to determine whether these levels had prognostic significance and whether they correlated with COX-2 expression and/or responded to inhibition of COX-2 or 5-LOX. METHODS: Pre- and post-treatment serum was collected from patients enrolled in CALGB 30203. Serum VEGF levels were determined using enzyme-linked immunosorbent assay methodology. Statistical analyses were performed to determine the correlation between pretreatment serum VEGF levels and time of overall survival. Pretreatment formalin fixed tissue was stained for 5-LOX and COX-2 by immunohistochemistry. RESULTS: The median baseline VEGF level was 502 pg/ml (range, 55-3453 pg/ml). Dichotomized serum VEGF levels at median inversely correlated with survival time (p = 0.008), as did VEGF levels as a continuous variable in multivariate analysis (p = 0.035). VEGF levels were significantly correlated neither with baseline COX-2 expression (Pearson r = 0.1524, p = 0.271) nor with 5-LOX expression. Treatment with COX-2 or 5-LOX inhibitors did not alter the levels. CONCLUSION: These data indicate that elevated serum VEGF is a negative prognostic variable in NSCLC. VEGF levels are neither correlated with baseline tumor COX-2 expression nor do they respond to COX-2 and/or 5-LOX inhibition plus chemotherapy.
1 Originating Grant
1 April 1982 - 31 March 2003
NATIONAL CANCER INSTITUTE
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):848-55.
Martin J Edelman; Chandra P Belani; Mark A Socinski; Rafat H Ansari; Coleman K Obasaju; Ruqin Chen; Matthew J Monberg; Joseph Treat;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(1):110-6.
Frank C Detterbeck; Mark A Socinski; Richard J Gralla; Martin J Edelman; Thierry M Jahan; David M Loesch; Steven A Limentani; Ramaswamy Govindan; M B Zaman; Zhishen Ye; et al.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):37-45.
Appears in this Publication
Author of this Publication